2B4 Stock Chart & Stats
€20.54
-€0.56(-2.72%)
At close: 4:00 PM EDT
€20.54
-€0.56(-2.72%)
Day’s Range― - ―
52-Week Range€15.50 - €25.84
Previous CloseN/A
Volume820.00
Average Volume (3M)375.00
Market Cap
€1.39B
Enterprise Value€13.69B
Total Cash (Recent Filing)€434.31M
Total Debt (Recent Filing)€10.13M
Price to Earnings (P/E)73.2
Beta0.60
Next Earnings
Oct 22, 2026EPS Estimate
0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.24
Shares Outstanding65,859,190
10 Day Avg. Volume472
30 Day Avg. Volume375
Financial Highlights & Ratios
PEG Ratio14.80
Price to Book (P/B)14.28
Price to Sales (P/S)10.54
P/FCF Ratio57.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.44
Revenue Forecast (FY)€132.35M
Bulls Say, Bears Say
Bulls Say
High-margin, Scalable Business ModelVery high gross margins and strong operating profitability indicate substantial value capture from the CERAMENT platform. If maintained as sales expand, this economics profile can fund commercial investment, support resilient earnings growth, and reinforce the scalability of the company’s procedure-driven model.
Strong Growth In Core Products And MarketsBroad-based growth across the United States and antibiotic-eluting CERAMENT suggests increasing clinical adoption rather than reliance on a single isolated product or region. Continued penetration of infection-related and trauma procedures can expand the company’s addressable market and strengthen its market position.
Conservative Balance Sheet And Improved Cash GenerationMinimal leverage gives BONESUPPORT substantial financial flexibility to invest in sales infrastructure, product development, and regulatory programs without depending heavily on external financing. Strong recent cash generation also improves resilience and provides capacity for disciplined capital allocation as the business grows.
Bears Say
Revenue Growth Is Decelerating From Earlier Hyper-growthAlthough growth remains solid, deceleration from the exceptionally strong 2023–2024 period raises the bar for sustaining the current earnings trajectory. Slower expansion could reduce operating leverage, moderate the pace of market-share gains, and make future performance more dependent on successful new indications and broader adoption.
Cash Generation Has A Volatile Recent HistoryThe sharp turnaround in cash generation is encouraging, but the recent history shows that cash conversion has not yet been proven across a full business cycle. Renewed volatility could constrain internally funded expansion and make reported profitability less dependable for long-term capital planning.
Regulatory And Reimbursement Outcomes Remain UncertainPotential regulatory and reimbursement progress could broaden product access, but the outcomes and timing remain outside management’s control. Delays or unfavorable decisions could postpone CERAMENT V commercialization, limit reimbursement benefits for CERAMENT G, and defer clinical validation that supports adoption.
BONESUPPORT HOLDING AB News
2B4 FAQ
What was BONESUPPORT HOLDING AB’s price range in the past 12 months?
BONESUPPORT HOLDING AB lowest stock price was €15.50 and its highest was €25.84 in the past 12 months.
What is BONESUPPORT HOLDING AB’s market cap?
BONESUPPORT HOLDING AB’s market cap is €1.39B.
When is BONESUPPORT HOLDING AB’s upcoming earnings report date?
BONESUPPORT HOLDING AB’s upcoming earnings report date is Oct 22, 2026 which is in 10 days.
How were BONESUPPORT HOLDING AB’s earnings last quarter?
BONESUPPORT HOLDING AB released its earnings results on Jul 16, 2026. The company reported €0.11 earnings per share for the quarter, beating the consensus estimate of €0.101 by €0.009.
Is BONESUPPORT HOLDING AB overvalued?
According to Wall Street analysts BONESUPPORT HOLDING AB’s price is currently Overvalued.
Does BONESUPPORT HOLDING AB pay dividends?
BONESUPPORT HOLDING AB does not currently pay dividends.
What is BONESUPPORT HOLDING AB’s EPS estimate?
BONESUPPORT HOLDING AB’s EPS estimate is 0.11.
How many shares outstanding does BONESUPPORT HOLDING AB have?
BONESUPPORT HOLDING AB has 65,859,190 shares outstanding.
What happened to BONESUPPORT HOLDING AB’s price movement after its last earnings report?
BONESUPPORT HOLDING AB reported an EPS of €0.11 in its last earnings report, beating expectations of €0.101. Following the earnings report the stock price went down -7.407%.
Which hedge fund is a major shareholder of BONESUPPORT HOLDING AB?
Currently, no hedge funds are holding shares in DE:2B4
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BONESUPPORT HOLDING AB
Bonesupport Holding AB (publ) is an orthobiologics company that specializes in the development and commercialization of injectable bioceramic bone graft substitutes. These products are utilized for treating bone voids and are available internationally, including in Europe and North America. Among its key offerings are CERAMENT Bone Void Filler, a synthetic, injectable, moldable, and drillable solution comprising hydroxyapatite, calcium sulfate, and the radio-contrast agent iohexol. Additionally, the company provides CERAMENT G, an injectable ceramic bone graft substitute infused with gentamicin, and CERAMENT V, a synthetic bone void filler containing vancomycin. Bonesupport is also advancing preclinical product candidates focused on promoting bone regrowth. These future solutions are being developed for applications such as trauma, revision arthroplasty, chronic osteomyelitis, oncology, and bone and foot infections related to diabetes. Founded in 1999, the company maintains its headquarters in Lund, Sweden.
2B4 Company Deck
2B4 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a predominantly positive operational and financial picture: strong revenue growth (30% FX-adjusted), high adjusted margins (29%), solid cash generation and pronounced U.S. launch momentum for CERAMENT G. Material positives include regulatory progress, proposed CMS reimbursement improvements, and healthy EUROW performance. Headwinds include a small set of U.S. accounts temporarily restricting usage (modestly dampening growth), higher commercial and incentive costs, minor gross margin impacts from write-downs and tariffs, and uncertainty around the timing of regulatory approvals and study publications. On balance the company's growth trajectory and scalable profitability outweigh the transitory challenges discussed.View all DE:2B4 earnings summaries